Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in the
western world, is an aggressive disease that remains incurable in approximately 30% of …

Diffuse large B-cell lymphoma (DLBCL), the most frequent subtype of lymphoid malignancy,
remains a significant clinical challenge, as∼ 30% of patients are not cured. Over the past …

Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous clinicopathologic entity
accounting for 30% of non-Hodgkin's lymphomas. The pathogenesis of DLBCL is complex …

The identification of genetic alterations that contribute to the malignant transformation of a B
cell into a DLBCL is helping to better understand the biology of this disease and to identify …

Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of
somatic mutations and structural alterations. However, the clinical significance of these …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with recognized
variability in clinical outcome, genetic features, and cells of origin. To date, transcriptional …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is
associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative …

Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is
characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity …